Welcome to our dedicated page for MEDIFAST SEC filings (Ticker: MED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MEDIFAST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MEDIFAST's regulatory disclosures and financial reporting.
BlackRock, Inc. reports beneficial ownership of 327,404 shares of Medifast, Inc. common stock, representing 2.9% of the class as of June 30, 2026. BlackRock has sole voting and dispositive power over all 327,404 shares and no shared voting or dispositive power. The filing notes that the position represents ownership of 5 percent or less of Medifast’s outstanding common stock. Various underlying persons have rights to dividends or sale proceeds for these shares, but no single person has an interest greater than five percent of Medifast’s total outstanding common shares.
Medifast announced a major brand transformation, rebranding its OPTAVIA lifestyle brand as Trilivy, a comprehensive metabolic health system focused on broader metabolic health rather than only weight loss.
The Trilivy system is built around Metabolic Synchronization, which the company describes as targeting visceral fat, preserving lean mass and supporting muscle health. Cited clinical research reports a 14% reduction in visceral fat and retention of 98% of lean mass at 16 weeks on its plan, and up to 10x more weight and 17x more fat loss for participants using a coach-supported program versus attempting weight loss alone. The program is organized into three phases—Reset, Refine and Renew—and is supported by new Trilivy Reset Fuelings enhanced with MetaVantage Technology and a nationwide network of independent coaches.
MEDIFAST INC director Kiai Parsa filed an amended initial ownership report detailing indirect holdings of common stock. The filing lists 17,003 shares of common stock held indirectly through one Steamboat Capital entity and 590,793 shares held indirectly through another Steamboat Capital entity. Footnotes explain that these entities are investment funds for which affiliated entities act as investment adviser and general partner, and that Parsa Kiai may be deemed to have a pecuniary interest in their holdings but disclaims beneficial ownership beyond that pecuniary interest.
Medifast, Inc. reports a senior legal leadership change. Effective May 29, 2026, Jason L. Groves, Esq., the company’s Chief Legal Officer & Corporate Secretary, resigned from his position.
On May 31, 2026, Mr. Groves and Medifast entered into a Separation Agreement. He will receive a one-time lump sum cash severance payment equal to one month of his annual base salary, less applicable taxes and withholdings, contingent on his non-revocation of the agreement and compliance with its terms. The company states that his departure was not due to any disagreement over operations, policies or practices, and it has begun searching for a permanent replacement.
Rose Jeffrey Matthew reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc director Jeffrey Matthew Rose reported equity-based compensation rather than open-market trading. On May 26, 2026, he received two awards of common stock with no cash price per share, both classified as grants or awards.
The filing shows an award of 6,739 shares of common stock, described in the footnotes as restricted stock units granted under Medifast’s Director's Deferred Compensation Plan in connection with annual director fees. Each unit represents one share and will vest in full on May 26, 2027.
A separate entry reports an additional 11,680 shares of common stock received as a grant or award. The footnotes explain that Rose elected to receive Medifast common stock in lieu of cash compensation for his annual service as a non-employee director. Following these transactions, his reported direct holdings include 18,419 shares in one line and 11,680 shares in another.
MEDIFAST INC director Kiai Parsa reported equity-based compensation awards rather than open-market trades. On May 26, 2026, he received 7,637 restricted stock units and a separate grant of 11,680 shares of common stock at no cash cost, in connection with his annual director fees.
According to the company’s Director's Deferred Compensation Plan, each unit represents one share of common stock, granted from the Amended and Restated 2012 Share Incentive Plan, and these shares will vest in full on May 26, 2027. The filing shows direct holdings associated with these awards of 19,317 and 11,680 shares, respectively, underscoring that this is a compensation-related acquisition, not a market purchase or sale.
Thomas Andrea B reported acquisition or exercise transactions in this Form 4 filing.
MEDIFAST INC director Andrea B. Thomas received an equity grant of 11,680 restricted stock units as part of annual director fees. The award was made under the company’s Director's Deferred Compensation Plan, with each unit representing one share of common stock. The RSUs, issued from the Amended and Restated 2012 Share Incentive Plan, will vest in full on May 26, 2027. Following this grant, Thomas directly holds 35,697.123 shares of Medifast common stock.
SCHLACKMAN SCOTT reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc. director Scott Schlackman received an award of 11,680 restricted stock units as part of his annual director fees. Each unit represents one share of common stock granted under the company’s share incentive plan and is scheduled to vest in full on May 26, 2027. Following this grant, Schlackman directly holds 42,228.707 shares of common stock.
Geary Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc. director Elizabeth A. Geary received a grant of 11,680 restricted stock units of common stock as part of her annual director fees under the company’s Director's Deferred Compensation Plan. The award was made at a grant price of $0.00 per share.
Each unit represents one share of Medifast common stock and will vest in full on May 26, 2027, subject to the plan terms. Following this grant, Geary’s reported direct holdings total 31,225 shares of Medifast common stock, reflecting routine, compensation-related equity issuance rather than an open-market purchase.
Xian Ming reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc. director Xian Ming received an annual grant of 11,680 cash-settled restricted stock units under the 2012 Share Incentive Plan. These units will vest in full on May 26, 2027, and each represents a right to receive the cash value of one share of common stock at vesting.
After this grant, Ming’s reported derivative holdings tied to common stock total 43,822.918 units. This is a compensation award, not an open-market stock purchase or sale.